Maintaining a Neutral Stance Amid Persistent AirSeal Headwinds and Execution Challenges

In a report released today, Matthew O’Brien from Piper Sandler downgraded Conmed to a Hold, with a price target of $39.00.

Matthew O’Brien has given his Hold rating due to a combination of factors, including persistent headwinds around the AirSeal franchise and broader execution issues. Although the competing product from ISRG did not completely erode AirSeal’s business, management’s communications around the challenge, coupled with operational missteps, have pressured the shares for roughly two years.

He sees no clear near-term catalyst to improve sentiment, despite the stock’s undemanding valuation and the company’s ability to pursue smaller bolt-on acquisitions. In his view, more attractive small and mid-cap opportunities exist elsewhere at this time, leading him to shift to a neutral stance and cut his price target to $39, now based on a lower earnings multiple reflecting the reduced conviction level.

In another report released on March 14, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $38.00 price target.